ProCE Banner Activity

CE / CME

Living Longer With HER2+ Breast Cancer: Sequencing Newer Therapies to Improve Survival

PCE On Demand Live Presentation

The management of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has evolved due to the availability of targeted therapies. To optimize patient outcomes, there is an ongoing need for education on treatment selection and sequencing, management of adverse events (AEs), and the importance of patient feedback in optimizing care. This activity provides expert advice on the management of advanced HER2-positive breast cancer and AEs associated with targeted therapies.

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Released: December 28, 2022

Expiration: December 27, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Rita Nanda

Rita Nanda, MD

Associate Professor of Medicine
Department of Medicine
Director, Breast Oncology
University of Chicago
Chicago, Illinois

Beth Sandy

Beth Sandy, MSN, CRNP

Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

ProCE Banner

Supporters

This program is supported by an educational grant from

Seagen

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

After completing this activity, participants should be better able to:

  • Implement individualized evidence-based and guideline-directed treatment plans for patients with HER2-positive breast cancer 

  • Apply optimized strategies to manage AEs, treatment administration, adherence, and patient education

  • Integrate patient education and feedback to optimize patient experiences during treatment and survivorship

Disclosure

All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Susan Moench, PhD, PA-C: independent contractor: Gilead, Merck.

Rita Nanda, MD: researcher (paid to institution): Arvinas, AstraZeneca, Celegene, Corcept, Genentech/Roche, Immunomedics/Gilead, Merck, OBI, Odonate, OncoSec, Pfizer, Seagen, Taiho; advisory board: AstraZeneca, BeyondSpring, Fuji Film, GE, Immunomedics/Gilead, Infinity, iTeos, Merck, OBI, OncoSec, Sanofi, Seagen.

Kristi Kay Orbaugh, RN, MSN, RNP, AOCN: speaker: AstraZeneca, BMS, DSI, Gilead, Lilly, Morphosys, Pfizer, Regeneron, Sanofi.

Beth Sandy, MSN, CRNP: speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

The planners and content peer reviewers from Partners for Advancing Clinical Education and Practicing Clinicians Exchange do not have any relevant financial relationships to disclose, except Kristi Kay Orbaugh, RN, MSN, RNP, AOCN and Susan Moench, PhD, PA-C, as noted above.

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 1.00 hour.

Release date: December 28, 2022
Expiration date: December 27, 2023

Format

This program has been made available online.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education, Practicing Clinicians Exchange, or any educational supporter.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

ANCC Credit Designation
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
Nurse planner: Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

 

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until December 27, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA planner: Susan Moench, PhD, PA-C, Edison New Jersey

 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.